Trump’s MFN Drug Pricing Policies: A Closer Look at the Impact and Challenges

Under President Donald Trump’s administration, the United States has pursued a strategy known as Most Favored Nation (MFN) policies to address prescription drug pricing disparities between the U.S. And other wealthy nations. These initiatives, which include the GENEROUS model and the TrumpRx portal, aim to reduce drug costs for American consumers. However, their effectiveness and long-term implications remain subjects of debate among experts and policymakers.

The GENEROUS Model: Aiming for Cost Reductions

The GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) model, developed by the Centers for Medicare and Medicaid Services (CMS), is a key component of the MFN strategy. This voluntary program seeks to negotiate supplemental drug rebates with pharmaceutical manufacturers based on prices paid in other countries. According to a White House report, the MFN framework in Medicaid is projected to save $64 billion over a decade. However, the accuracy of these projections is uncertain due to unclear assumptions and the confidential nature of agreements with drug manufacturers.

Critics argue that the model does not directly address manufacturers’ pricing power for list prices, which remain significantly higher in the U.S. Compared to other nations. Studies indicate that U.S. Drug prices are approximately three times higher than in other countries. While the GENEROUS model aims to align U.S. Prices with those in peer nations, its effectiveness depends on